Dopamine and glutamate stand out as the pair of neurotransmitters that have received the most attention in explaining schizophrenia symptoms, based on decades of research highlighting their imbalances.

Core Theories

The dopamine hypothesis dominates discussions, linking excess dopamine activity in certain brain pathways (like mesolimbic regions) to positive symptoms such as hallucinations and delusions. Meanwhile, glutamate dysfunction , particularly reduced NMDA receptor activity, is tied to negative symptoms (e.g., social withdrawal) and cognitive deficits, with studies showing excitatory imbalances. This dual focus has driven antipsychotic drug development, from dopamine blockers to emerging glutamatergic modulators.

Why This Pair?

  • Historical Spotlight : Dopamine gained traction in the 1950s-60s with chlorpromazine's success blocking D2 receptors; glutamate surged in the 1980s via PCP/ketamine models mimicking schizophrenia.
  • Evidence Strength : PET scans confirm striatal dopamine surges in patients; glutamate studies reveal low cortical levels correlating with symptom severity.
  • Interplay : Dopamine hyperactivity may stem from glutamate deficits, creating a "final common pathway" for symptoms.

Other Contenders

Serotonin (5-HT2A) pairs often with dopamine in atypical antipsychotics' action, aiding negative symptoms. GABA offers promise for inhibitory balance but trails in research volume. No pair eclipses dopamine-glutamate for attention, per reviews up to 2025.

Recent Trends

As of 2025, forums and studies trend toward glutamate therapies amid dopamine blocker limits (e.g., side effects). Ongoing trials explore dual-target drugs.

TL;DR : Dopamine (positive symptoms) and glutamate (negative/cognitive) top research focus.

Information gathered from public forums or data available on the internet and portrayed here.